Skip to main content

Table 2 Summary of clinical and demographic data for the set of Caucasian IBD patients

From: Nucleotide-binding oligomerization domain containing 1 (NOD1) haplotypes and single nucleotide polymorphisms modify susceptibility to inflammatory bowel diseases in a New Zealand caucasian population: a case-control study

  CD
n (%)
UC
n (%)
IC
n (%)
Gender    
Female 249 (64.2) 214 (52.8) 15 (55.6)
Male 139 (35.8) 191 (47.2) 12 (44.4)
Age at first diagnosis    
Below 17 39 (10.0) 26 (6.4) 0
Between 17 and 40 199 (51.3) 184 (45.4) 15 (55.6)
Above 40 150 (38.7) 195 (48.2) 12 (44.4)
CD location    
Ileal 125 (32.2)   
Colonic 169 (43.6)   
Ileocolonic 90 (23.2)   
Upper GI 4 (1.0)   
UC location    
Proctitis   140 (34.6) 3 (11.1)
Left colon   107 (26.4) 5 (18.5)
Pancolitis   154 (38.0) 19 (70.4)
Unknown   4 (1.0) 0
Behaviour    
Non-stricturing, non-penetrating perianal disease 47 (21.5)   
Stricturing perianal disease 46 (38.0)   
Penetrating perianal disease 17 (35.4)   
Any relative with IBD: Yes (n = 143) 74 (19.1) 65 (16.1) 5 (18.5)
Bowel resection: Yes (n = 214) 142 (36.6) 70 (17.3) 2 (7.4)
Smoker at diagnosis: Yes (n = 147) 97 (25.7) 49 (12.3) 2 (7.7)
Ever used immunomodulators: Yes (n = 296) 203 (52.3) 86 (21.2) 8 (29.6)
Extraintestinal manifestations: Yes (n = 142) 75 (19.3) 64 (15.8) 3 (11.1)